Related Experiment Videos
When, for whom and how to use sibutramine?
1Research Department of Human Nutrition, The Royal Veterinary and Agricultural University, Frederiksberg, Copenhagen, Denmark. Arne.v.astrup@fhe.kvl.dk
Summary
Sibutramine, a weight management drug, aids long-term weight control alongside diet and exercise. It significantly increases patient response rates in weight reduction programs for obese and overweight individuals with risk factors.
Area of Science:
- Pharmacology
- Clinical Medicine
- Weight Management
Background:
- Sibutramine represents a new class of weight management medications.
- It is prescribed as a supplement to diet and exercise for long-term weight control.
- Regulatory criteria for its use, efficacy, and side-effect profiles are under review.
Purpose of the Study:
- To evaluate sibutramine's efficacy, side-effect profile, and benefits in various patient groups.
- To assess sibutramine's use based on European Union regulatory criteria.
- To review data on sibutramine's effectiveness and safety in adults aged 18-65.
Main Methods:
- Review of European Union regulatory criteria for sibutramine.
- Analysis of efficacy, side-effect profile, and patient group benefits.
- Consideration of data from clinical studies, including the STORM study.
Main Results:
- Sibutramine, as an adjunct to diet and exercise, leads to 3-5 times more patients achieving over 5% weight maintenance.
- The European Union permits continuous treatment for up to 1 year.
- The US Food and Drug Administration extended clearance to 2 years based on the STORM study.
- Indicated for obese patients (BMI > 30 kg/m2) and overweight patients (BMI > 27 kg/m2) with obesity-related risk factors like type 2 diabetes or dyslipidemia.
Conclusions:
- Sibutramine is an effective adjunct for weight management in specific patient populations.
- Treatment duration and patient selection criteria are guided by regulatory approvals and clinical data.
- Further research may be needed for age groups outside the 18-65 range.